---
title: "Pharmos Corporation"
url: https://duttonassociates.com/research/PARS/
description: "Company profile for Pharmos Corporation (PARS) as published by Dutton Associates, with company facts and the firm's published research on the company."
---

# Pharmos Corporation

PARS

Nasdaq

Suite 311
99 Wood Avenue South
Iselin, NJ 08830
(732) 452-9556

Pharmos discovers, develops and commercializes novel therapeutics to treat a range of neurological disorders such as traumatic brain injury (TBI), stroke, neuropathic pain, Parkinson's disease and other CNS and peripheral neuro-inflammatory indications. Pharmos' researchers have developed a family of novel, non-psychotropic cannabinoids, dextrocannabinoids, for the treatment of neurological, vascular and other conditions involving inflammatory processes.

Dexanabinol is the first neuroprotective product under clinical development at Pharmos. Patients are currently being enrolled in centers in Belgium, Finland, France, Germany, Israel, Italy, the Netherlands, Spain and the United Kingdom. Upon receipt of regulatory approvals, enrollment of patients will commence in up to seven additional international countries, including the United States. Enrollment of approximately 860 total patients is anticipated by the end of 2003.

With the aid of computational chemistry, Pharmos has constructed a library of dextrocannabinoid compounds comprising two major chemical groups. The first is the tricyclic family of compounds, of which dexanabinol is the prototype. These compounds have the generic ability to inhibit NMDA receptors and to block COX-2, cytokines and chemokine activation, thereby acting as powerful anti-inflammatory and neuroprotective agents against diseases such as TBI, stroke, neuropathic pain and other neuro-inflammatory indications.

The second group is the bicyclic family of compounds, which specifically bind to CB2 receptors. Because CB2 receptors are present in all cells of the immune system, Pharmos is evaluating the potential of bicyclic dextrocannabinoid compounds as modulators of the immune system and for their affect on auto-immune diseases.

Pharmos is actively studying compounds from its dextrocannabinoid library in pre-clinical programs targeting various CNS and peripheral disorders, including stroke, neuropathic pain, Parkinson's disease, renal ischemia and others.

## Company Facts

**Symbol**: PARS

**Exchange**: Nasdaq

**Equity Data**: (as of 8/01/02)

**Shares Outstanding**: 56,500,000 shares

**Recent Trading Price**: $1.05

**J.M. Dutton Analyst**: Sherry Grisewood, CFA

**Current rating**: Strong Spec. Buy

**Price target**: $3.75

**Rating established**: 11/03/2005

www.pharmoscorp.com

[Back to the coverage register](https://duttonassociates.com/research/)

[Rating schedule](https://duttonassociates.com/Ratings/Ratings.html)

## Published Research

- 10/01/2003Research noteFDA Gives Pharmos Corporationís Lead Product Fast Track Status; Raising Target Price to $3 From $2.50
- 08/13/2003Research notePharmos Reports Second Quarter 2003 Results, Progress In Clinical Trials
- 07/02/2003Research notePharmos: First US Patient for Phase III Traumatic Brain Injury Trial Enrolled
- 06/18/2003Research reportPharmos Corporation Speculative Buy Rating Maintained
- 06/12/2003Research notePharmos Receives Notice of Allowance for US Patent on Dexanabinol
- 03/13/2003Research notePharmos Year End Financial Results And Update on Clinical Trial Status
- 02/27/2003Research reportPharmos Corporation Speculative Buy Rating Issued